.jpeg)
2026-08-14 03:20:41
This article systematically interprets Osimertinib, a core therapeutic drug for EGFR mutation-positive non-small cell lung cancer, covering pharmacological efficacy, common and serious adverse reactions, indications, usage and dosage, drug interactions and key points for special populations, providing a comprehensive reference for standardized clinical medication.
2026-08-14 02:50:16
Sotorasib (brand name Lumakras) is the world's first approved targeted drug for KRAS G12C mutations, used in precision treatment of non-small cell lung cancer and colorectal cancer. This article explains its efficacy limits, approved indications, mechanism of action, and safety considerations to help patients set realistic treatment expectations.
2026-08-13 04:17:25
Trametinib is a highly selective MEK1/2 inhibitor used in BRAF V600-mutant melanoma, NSCLC, low-grade glioma, and other solid tumors. This article details refrigeration requirements, fasting dosing protocols, missed-dose management, eligible patient populations, and special-population considerations to support safe and standardized treatment.
2026-08-13 04:02:58
Asciminib (brand name SCEMBLIX) is the first STAMP-class targeted therapy for chronic myeloid leukemia. This article clarifies nomenclature consistency, strict fasting requirements, missed-dose protocols, and safety monitoring essentials to help patients avoid medication errors and optimize therapeutic outcomes.
2026-08-13 03:58:16
Belzutifan (brand name Welireg) is the first oral hypoxia-inducible factor-2α (HIF-2α) inhibitor, holding a unique position in managing VHL disease-associated tumors and clear cell renal cell carcinoma. This article systematically reviews its phased treatment strategy, survival outcomes, efficacy-modifying factors, adverse event management, and special-population considerations.
2026-08-13 03:52:54
Cabergoline is a long-acting dopamine receptor agonist used primarily for hyperprolactinemia. This guide systematically covers contraindicated populations, standard dosing regimens, cost estimates, long-term cardiac monitoring requirements, and overseas version selection to help patients plan safe and sustainable treatment.
2026-08-12 04:21:50
Pemigatinib and Anlotinib are both anti-tumor targeted agents, yet they differ fundamentally in mechanism, target specificity, and applicable cancer types. This article provides a systematic comparison across molecular mechanisms, indications, precision, adverse effects, and treatment selection to guide informed clinical decisions.
2026-08-12 04:11:20
Enasidenib (brand name IDHIFA) is an oral, selective IDH2 inhibitor indicated for adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring an IDH2 mutation. This article covers its indications, dosing, adverse effects, mechanism of action, storage, and special-population considerations.
2026-08-11 06:06:06
Midostaurin and gilteritinib are both FLT3-targeted agents but differ fundamentally in selectivity, indications, and treatment phase. This article systematically compares their mechanisms, clinical roles, and appropriate use contexts in precision AML management.
2026-08-11 05:57:10
Lapatinib is an oral small-molecule tyrosine kinase inhibitor targeting HER2 and EGFR pathways in HER2-positive breast cancer. This article clarifies its therapeutic positioning, clinical applications, and the critical role of HER2 testing in treatment decisions.
2026-08-11 05:29:21
Filgotinib is an oral selective JAK1 inhibitor used for rheumatoid arthritis and ulcerative colitis. This article explains its targeted immune-modulating mechanism, therapeutic advantages, and key safety considerations for long-term use.
2026-08-11 05:22:22
Lapatinib is an oral HER2-targeted anticancer agent. This article covers dosing schedule, food interactions, combination regimens, missed-dose management, drug interactions, and safety monitoring for patients with HER2-positive breast cancer.
